Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study

Bartoli F.;Cavaleri D.;Callovini T.;Riboldi I.;Crocamo C.;D'Agostino A.;Martinotti G.;Bertolini F.;Ostuzzi G.;Barbui C.;Carra G.;Boschello F.;Gastaldon C.;Mazzi M. A.;Nose M.;Papola D.;Perini G.;Piccoli A.;Pievani M.;Purgato M.;Ruggeri M.;Tedeschi F.;Terlizzi S.;Turrini G.;Caroleo M.;De Fazio P.;Magliocco F.;Raffaele G.;Chirico M.;Ferrato F.;Limosani I.;Mastromo D.;Monzani E.;Ostinelli E. G.;Porcellana M.;Restaino F.;Annese P. M.;Bolognesi S.;Cerretini M.;De Capua A.;Debolini S.;Del Zanna M.;Fargnoli F.;Giannini A.;Luccarelli L.;Lucii C.;Pierantozzi E.;Tozzi F.;Bardicchia F.;Cardamone G.;Facchi E.;Magnani N.;Soscia F.;Biancosino B.;Zotos S.;Giacomin M.;Pompei F.;Spano M.;Zonta F.;Buzzi A.;Callegari C.;Calzolari R.;Caselli I.;Diurni M.;Giana E. L.;Ielmini M.;Milano A.;Poloni N.;Sani E.;Zizolfi D.;Alberini G.;Bortolaso P.;Cazzamalli S.;Costantini C.;Di Caro A.;Paronelli C.;Piantanida S.;Piccinelli M.;Alessandro P.;Barbanti S. V.;D'Ippolito C.;Gozzi M.;Moretti V.;Corbo M.;Di Capro L.;di Giannantonio M.;Fiori F.;Lorusso M.;Mancini V.;Viceconte D.;Calandra C.;Luca M.;Signorelli M. S.;Suraniti F.;Balzarro B.;Boncompagni G.;Caretto V.;Emiliani R.;Lupoli P.;Menchetti M.;Rossi E.;Storbini V.;Tarricone I.;Terzi L.;Boso M.;Catania C.;De Paoli G.;Risaro P.;Aspesi F.;Bava M.;Bono A.;Brambilla G.;Castagna G.;Lucchi S.;Nava R.;Provenzi M.;Tabacchi T.;Tremolada M.;Verrengia E.;Barchiesi M.;Oriani M. G.;Aguglia A.;Ferro M.;Ghio L.;Beneduce R.;Laffranchini L.;Magni L. R.;Rossi G.;Tura G. B.;Addeo L.;Balletta G.;De Vivo E.;Di Benedetto R.;Parise V. F.;Carpiniello B.;Pinna F.;Pecile D.;Mattei C.;Bonavigo T.;Fabrici E. P.;Panarello S.;Peresson G.;Vitucci C.;Pacetti M.;Gardellin F.;Strizzolo S.;Cossetta E.;Fizzotti C.;Moretti D.;Di Gregorio L.;Sozzi F.;Colli G.;La Barbera D.;Laurenzi S.

2022-01-01

---

Abstract

In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.